FATE THERAPEUTICS INC 8-K

What Happened

• On February 26, 2026, Fate Therapeutics, Inc. (FATE) filed a Form 8-K (Item 2.02) stating that the company issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The press release is attached to the 8‑K as Exhibit 99.1. The filing was signed by President and CEO Bahram Valamehr, Ph.D., MBA.

Key Details

• Filing date: February 26, 2026 (Form 8-K).
• Reporting period covered by the press release: quarter and year ended December 31, 2025.
• Exhibit attached: 99.1 — press release dated February 26, 2026.
• Items reported on the Form 8-K: 2.02 (Results of Operations and Financial Condition) and 9.01 (exhibits).

Why It Matters

• Earnings and year‑end financial results are material to investors because they typically include revenue, profit/loss, cash position and business progress that affect valuation and near‑term expectations. This 8‑K indicates those results were publicly released on Feb. 26, 2026.
• The Form 8‑K itself does not present the numeric financials; investors should review Exhibit 99.1 (the company’s press release) and any subsequent SEC filings (e.g., the annual report or 10‑K) for the detailed figures and management commentary.